Skip to content
Screener

AptarGroup ATR Cash & Equivalents

Cash & Equivalents at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$435.8M-14.5%
Trimas logo
TrimasTRS
$1.31B+3,904%
Silgan Holdings logo
Silgan HoldingsSLGN
$351.53M+10.7%
Amcor logo
AmcorAMCR
$1.59B-22.4%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$163.99M+165%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$888.8M+1,598%

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$8.69B-4.7%
Enterprise value$9.9B-2.2%
P/E22.5×-0.8×
P/S2.3×-0.3×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: AptarGroup’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 11:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000896622-26-000092
In thousands, brackets denote cash outflows / Three Months Ended March 31,20262025
Proceeds from stock option exercises18,5163,375
Purchase of treasury stock(99,973)(80,000)
Redeemable noncontrolling interest89
Net Cash Used by Financing Activities(230,340)(134,777)
Effect of Exchange Rate Changes on Cash(3,150)10,662
Net Decrease in Cash and Equivalents and Restricted Cash(179,895)(98,005)
Cash and Equivalents and Restricted Cash at Beginning of Period404,849223,844
Cash and Equivalents and Restricted Cash at End of Period$224,954$125,839

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is AptarGroup's cash & equivalents?
AptarGroup (ATR) reported cash & equivalents of $224.95M in Q1 2026.
How has AptarGroup's cash & equivalents changed year-over-year?
AptarGroup's cash & equivalents increased by 78.8% year-over-year, from $125.84M to $224.95M.
What is the long-term trend for AptarGroup's cash & equivalents?
Over 5 years (2020 to 2025), AptarGroup's cash & equivalents has grown at a 5.8% compound annual growth rate (CAGR), from $304.97M to $404.85M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about AptarGroup's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude